Compare AKBA & FUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | FUNC |
|---|---|---|
| Founded | 2007 | 1900 |
| Country | United States | United States |
| Employees | N/A | 343 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.0M | 283.6M |
| IPO Year | 2014 | 2012 |
| Metric | AKBA | FUNC |
|---|---|---|
| Price | $1.23 | $44.57 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.67 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 26.8K |
| Earning Date | 05-07-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 2.80% |
| EPS Growth | ★ 93.94 | 19.68 |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $18,426,000.00 |
| Revenue This Year | N/A | $13.05 |
| Revenue Next Year | N/A | $6.56 |
| P/E Ratio | ★ N/A | $42.66 |
| Revenue Growth | N/A | ★ 4.01 |
| 52 Week Low | $0.82 | $31.80 |
| 52 Week High | $3.81 | $46.30 |
| Indicator | AKBA | FUNC |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 56.06 |
| Support Level | $1.16 | $41.34 |
| Resistance Level | $1.52 | $46.27 |
| Average True Range (ATR) | 0.07 | 1.49 |
| MACD | -0.02 | -0.25 |
| Stochastic Oscillator | 7.59 | 61.16 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.